Treatment of mycoses with itraconazole.

摘要: The efficacy of itraconazole, a new oral triazole, was evaluated at doses 50-400 mg/day in 64 courses: 39 with coccidioidomycosis, and 25 other mycoses. Among patients 21 had pulmonary disease; 10, bone joint; 8, lymphatic; 6, skin soft tissue; 3, meningeal; 1, urogenital. After mean 7.1 months treatment, 17 27 evaluable courses (63%) have shown full response; 8 (30%), partial 2 (7%), no response. Response to treatment higher shorter duration illness previous treatment. 12 two five responders off therapy relapsed. In mycoses, diagnoses include aspergillosis six patients; histoplasmosis tinea three each; alternariosis, candidiasis, cryptococcosis, blastomycosis, chromomycosis pseudallescheriosis one. 9.4 14 23 (61%) (8%), 7 All blastomycosis responded therapy. There are relapses among after 9.2 512 patient therapy, toxicity has been minimal. Mean serum levels receiving 200 mg twice daily range from 3.9 5.9 micrograms/ml for hr dosing, peak wide interpatient variability. Itraconazole is well tolerated continued demonstrate the variety systemic superficial